Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2566 to 2580 of 9030 results

  1. Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]

    In development Reference number: GID-TA11025 Expected publication date:  10 February 2027

    Technology appraisal guidance
    In development

  2. Obinutuzumab for treating serologically active extra-renal lupus [ID6670]

    In development Reference number: GID-TA11886 Expected publication date:  13 May 2027

    Technology appraisal guidance
    In development

  3. Thermocoagulation for the treatment of piles and anal fistula

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  4. Digital technologies to aid the scoring and interpretation of diagnostic sleep studies for obstructive sleep apnoea and rare sleep disorders

    In development Reference number: GID-HTG10174 Expected publication date: TBC

    HealthTech guidance
    In development

  5. Renal sympathetic denervation for resistant hypertension

    In development Reference number: GID-HTG10527 Expected publication date: TBC

    HealthTech guidance
    In development

  6. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 4 June 2026.

    Technology appraisal guidance
    In consultation

  7. Epilepsies in children, young people and adults: draft guidance consultation

    We are listening to your views on this NICE guideline. Comments close 27 May 2026.

    NICE guideline
    In consultation

  8. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]

    In development Reference number: GID-TA11254 Expected publication date:  06 August 2026

    Technology appraisal guidance
    In development

  9. Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]

    In development Reference number: GID-TA11116 Expected publication date:  11 November 2026

    Technology appraisal guidance
    In development

  10. Sugemalimab with chemotherapy for untreated advanced non-small-cell lung cancer [ID6758]

    In development Reference number: GID-TA12462 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Diabetic foot problems: prevention and management - topical wound oxygen therapy for diabetic foot ulcers

    Awaiting development Reference number: GID-NG10552 Expected publication date: TBC

    NICE guideline
    Awaiting development

  12. Teprotumumab for treating thyroid eye disease (deferred appraisal of D1) [ID6756]

    In development Reference number: GID-TA11995 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  13. Blood-based biomarker tests for surveillance in people at risk of hepatocellular carcinoma

    In development Reference number: GID-HTG10175 Expected publication date: TBC

    HealthTech guidance
    In development

  14. Aggressive behaviour in people receiving NHS or social care: prevention and management

    In development Reference number: GID-NG10432 Expected publication date:  28 January 2027

    NICE guideline
    In development

  15. Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]

    Awaiting development Reference number: GID-TA11284 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development